Additionally, recent advancements in radioimmunotherapy targeting DLL3 indicate encouraging antitumor activity with minimal toxicity, highlighting its potential as an important future therapeutic modality for SCLC [84]. The gene discussed is DLL3; the disease is small cell lung carcinoma.